Tuesday, 6 January 2015

INE Friday 16th January Dendritic Cells

The January meeting of Immunology North East will take place at 3pm on Friday 16th January (refreshments from 2.30pm) in the Research Beehive, Newcastle University room 2.21.  Please note change of day and time.   

 

 

Professor Jolanda de Vries from Radboud University Medical School, Nijmegen, the Netherlands will be presenting

 

"Natural dendritic cell vaccines to combat and prevent cancer"

 

 

 

Should you wish to speak to Jolanda during her visit to Newcastle please contact Dr Catharien Hilkens e-mail: catharien.hilkens@newcastle.ac.uk

 

Research Interests

Jolanda de Vries is Professor at the Department of Tumor Immunology at the Nijmegen Centre for Molecular Life Sciences. She was one of the pioneers to translate dendritic cell biology into potential clinical applications. The first clinical phase I/II studies in which patients were vaccinated with DCs loaded with tumor-specific peptides were initiated in 1997. She also developed a novel immuno-monitoring assay that is highly predictive for extended survival after vaccination with DCs (J Clin Oncology 2005). Her primary scientific interest continues along the line of DC-immunotherapy and in particular the migration and imaging of DC. For example, in-vivo imaging of ex-vivo labeled cells using MRI (Nature Biotechnology 2005). New opportunities for other cell-types (e.g. subsets of DCs) are now being developed. She recently completed the first plasmacytoid DC vaccination trial.

 

More details on Deborah's research can be found at

http://www.tumor-immunology.com/our-people/person/?personID=1498

 

 

Recent Publications:

1.     Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, Adema GJ, Brown GD, Figdor CG, de Vries IJ, The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood, 2012. 119(10): 2284-92.

http://bloodjournal.hematologylibrary.org/cgi/pmidlookup?view=long&pmid=22234694

2.     Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ,Nierkens S, Schreibelt G, de Boer A, Van Herpen CM, Kaanders JH, van Krieken JH, Adema GJ, Figdor CG, de Vries IJ. Platinum-based drugs disrupt STAT6-mediatedsuppression of immune responses against cancer in humans and mice. J Clin Invest, 2011. 121(8): 3100-8.

http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21765211/

Aarntzen EH, Srinivas M, De Wilt JH, Jacobs JF, Lesterhuis WJ, Windhorst AD, Troost EG, Bonenkamp JJ, van Rossum MM, Blokx WA, Mus RD, Boerman OC, Punt CJ, Figdor CG, Oyen WJ, de Vries IJ. Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PETimaging. Proc Natl Acad Sci U S A, 2011 108(45):1 8396-9.

http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22025695/

3.     Schreibelt G, Benitez-Ribas D, Schuurhuis D, Lambeck AJ, van Hout-Kuijer M, Schaft N, Punt CJ, Figdor CG, Adema GJ, de Vries IJ, Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood, 2010. 116(4): 564-74.

http://bloodjournal.hematologylibrary.org/cgi/pmidlookup?view=long&pmid=20424184


No comments:

Post a comment

Note: only a member of this blog may post a comment.